Pair Name	Beta-Elemene, Bortezomib
Disease Info	[ICD-11: 2C10]	Pancreatic cancer		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G2/M phase
Gene Regulation	Up-regulation	Cleavage	CASP3	hsa836
	Down-regulation	Expression	CCNB1	hsa891
	Up-regulation	Expression	CDKN1A	hsa1026
	Down-regulation	Expression	NFKBIA	hsa4792
	Down-regulation	Expression	RELA	hsa5970
	Down-regulation	Expression	TP53	hsa7157
In Vitro Model	PANC-1	Pancreatic ductal adenocarcinoma	Homo sapiens (Human)	CVCL_0480
	BxPC-3	Pancreatic ductal adenocarcinoma	Homo sapiens (Human)	CVCL_0186
In Vivo Model	Bortezomib or elemene alone inhibited the tumor growth to a certain extent, while the combination treatment significantly enhanced the antitumor activity relative to bortezomib alone assessed by tumor growth curve and endpoint tumor weight, suggesting that elemene boosts bortezomib’s anti-pancreatic cancer activity, and their combination displays significant antitumor efficacy with no obvious systematic toxicity.
Result	Elemene sensitizes pancreatic cancer cells to bortezomib by enhancing proteasome inhibition via molecular patch mechanism